WO2023144053 - HETEROCYCLIC DERIVATIVES
National phase entry is expected:
Publication Number
WO/2023/144053
Publication Date
03.08.2023
International Application No.
PCT/EP2023/051464
International Filing Date
23.01.2023
Title **
[English]
HETEROCYCLIC DERIVATIVES
[French]
DÉRIVÉS HÉTÉROCYCLIQUES
Applicants **
MERCK PATENT GMBH
Inventors
HEINRICH, Timo
SCHLESIGER, Sarah
Priority Data
22153540.4
26.01.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2502 | |
| EPO | Filing, Examination, Granting | 10012 | |
| Japan | Filing, Examination, Granting | 2183 | |
| South Korea | Filing, Examination, Granting | 2017 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
22,654
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.[French]
ont les significations indiquées dans la revendication 1, dégradent les protéines cibles, et peuvent être utilisés, entre autres, pour le traitement de maladies telles que le cancer, la sclérose en plaques, les maladies cardiovasculaires, les lésions du système nerveux central et différentes formes d'inflammation.